Wissam Aljundi, Loay Daas, Shady Suffo, Berthold Seitz, & Alaa Din Abdin. (2024). First-Year Real-Life Experience with Intravitreal Faricimab for Refractory Neovascular Age-Related Macular Degeneration. MDPI AG.
Chicago Style (17th ed.) CitationWissam Aljundi, Loay Daas, Shady Suffo, Berthold Seitz, and Alaa Din Abdin. First-Year Real-Life Experience with Intravitreal Faricimab for Refractory Neovascular Age-Related Macular Degeneration. MDPI AG, 2024.
MLA (9th ed.) CitationWissam Aljundi, et al. First-Year Real-Life Experience with Intravitreal Faricimab for Refractory Neovascular Age-Related Macular Degeneration. MDPI AG, 2024.
Warning: These citations may not always be 100% accurate.